Objective To explore the clinical efficacy of Feilike mixture combined with budesonide formoterol powder inhalants in the treatment of cough variant asthma (CVA) and its effect on airway inflammation. Methods A total of 72 patients with CVA enrolled in Respiratory Medicine Beijing First Hospital of Integrated Chinese and Western Medicine were selected for the study and randomly divided into the control group (n=36, treated with budesonide formoterol powder inhalants) and the experimental group (n=36, treated with budesonide formoterol powder inhalants and Feilike mixture). The clinical efficacy, pulmonary function, airway inflammation and adverse reactions were compared between the two groups. Results The total effective rate was 94.44% in the experimental group, which was significantly higher than that in the control group with 77.78%. After treatment, the day or nocturnal cough symptom scores, one-second forced expiratory volume (FEV1), FEV1/forced vital capacity (FVC), the ratio of PEF (PEF pred%) and interleukin-10(IL-10) level were significantly higher than those before treatment, After treatment, the levels of the eosinophil (EOS) percentage, inflammatory mediators interleukin-4(IL-4) and interleukin-5(IL-5) were significantly decreased in the two groups, and the changing degree in the experimental group was significantly higher than that in the control group. There was no significant adverse reaction between the two groups as well as the incidence rate of adverse reactions. Conclusion The use of Feilike mixture combined with budesonide formoterol powder inhalants can have significant effects in the treatment of CVA children, such as relieving the cough symptoms of children and improving lung function and airway inflammation with high safety.